Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treat-to-target by Email During Urate-lowering Therapy in Gout
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
Gout is secondary to urate crystal deposition after chronic elevation of serum urate level (SUL). Long-term lowering SUL below 360 µmol/L allows dissolution of deposited crystals and disease cure. There is currently a paradoxical observation: while urate-lowering therapy (ULT) is available and efficient there is an increase of gout prevalence and severity. The apparent failure of ULT in gout management is due to several causes including unadjusted dosage, no SUL verification, irregular follow-up and low treatment compliance. In contrast, a nurse-led treat-to-target (T2T) strategy with regular adaptations of ULT until reaching SUL target allows gout cure in more than 90% of patients. We hypothesize that an electronic messaging-led T2T strategy will allow obtaining similar results. The aim of this study is to demonstrate that email-led T2T strategy during ULT is superior to usual care.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
204
Start Date
2021-12-15
Completion Date
2026-12-31
Last Updated
2026-02-04
Healthy Volunteers
No
Interventions
Cleanweb electronic messaging ePro
Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
Usual follow-up
Adaptation and follow-up of ULT according to referring physician's habits
Locations (2)
Hopital LARIBOISIERE - Rhumatologie
Paris, France
Rhumathology department
Paris, Île-de-France Region, France